A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > BUSINESS
BUSINESS
- Ono to Transfer 5 Established Injectable Brands to Maruishi
October 2, 2018
- FDA OKs Pediatric Label Expansion for Fycompa: Eisai
October 2, 2018
- Alnylam Files Patisiran in Japan, Anticipates Nod in Mid-2019
October 2, 2018
- Astellas Seeks Approval for Japan’s 1st HIF-PH Inhibitor Roxadustat
October 2, 2018
- Wholesalers See “Some Reduction in Yakkasa” in Price Negotiations under New Guidelines: Will Reduction Continue?
October 2, 2018
- Maruho Licenses Cancer Stomatitis Treatment from NCC
October 2, 2018
- Konica Minolta Embarks on Precision Medicine Biz, Ex-GSK/AZ Exec Takes Helm
October 1, 2018
- 5 Years after Transparency Guidelines Rollout, R&D Costs Halve while Dining Outlays About to Disappear
October 1, 2018
- Maruho Takes Over Differin Gel Marketing Authorization from Galderma
October 1, 2018
- Vortioxetine Filed in Japan for MDD: Takeda/Lundbeck
October 1, 2018
- Hisamitsu Files Transdermal Parkinson’s Disease Drug in Japan
October 1, 2018
- 2 Camps of Biosimilar Makers Seek Japan Approval for Nesp Follow-Ons
October 1, 2018
- Takeda Touts Progress in R&D Makeover, Departure from Small Molecules
September 28, 2018
- Kyorin, Teijin Dissolve Capital Alliance
September 28, 2018
- Alnylam Plants Flag in Japan Soil, Eyes 4 RNAi Therapeutic Launches in 5 Years
September 28, 2018
- Number of Sales Reps in 43 Pharmas Dwindles by 4,906 in 4 Years: Survey
September 28, 2018
- Daiichi Sankyo Begins PIII Breast Cancer Trials for DS-8201
September 27, 2018
- IBM Japan Joins Takeda’s Shonan iPark
September 27, 2018
- Celgene Seeks Japan OK for Pomalyst Triplet for MM
September 27, 2018
- Alunbrig Outstrips Xalkori in Front-Line ALK NSCLC, Cuts Disease Progression or Death Risks by 51%: Takeda
September 27, 2018
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…